These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27928955)

  • 1. Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme.
    Daniilides K; Lougiakis N; Evangelidis T; Kostakis IK; Pouli N; Marakos P; Mikros E; Skaltsounis AL; Bach S; Baratte B; Ruchaud S; Karamani V; Papafotika A; Christoforidis S; Argyros O; Kouvari E; Tamvakopoulos C
    Anticancer Agents Med Chem; 2017; 17(7):990-1002. PubMed ID: 27928955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
    Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
    Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
    Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
    Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
    Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
    Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
    Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
    Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
    Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X; Quan Y; Wang Y; Wang Y; Li Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
    Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
    Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
    Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
    J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
    Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
    Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
    Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
    Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antiproliferative activity of 2,4-disubstituted 6-aryl-7H-pyrrolo[3,2-d]pyrimidin-7-one 5-oxides.
    Pudziuvelyte E; Ríos-Luci C; León LG; Cikotiene I; Padrón JM
    Bioorg Med Chem; 2009 Jul; 17(14):4955-60. PubMed ID: 19527934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
    Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
    Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.